Audited Standalone Financial Results for the quarter and financial year ended March 31, 2026 and declaration of unmodified opinion on the Financial Results.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zenotech Laboratories reported revenue from operations of ₹3,956.20 lakhs for FY2026, marginally up from ₹3,897.57 lakhs in FY2025. However, the company swung to a net loss of ₹107.21 lakhs compared to a profit of ₹561.29 lakhs in the previous year—a sharp decline driven by higher tax expenses including ₹477.18 lakhs in deferred tax charges and ₹526.11 lakhs total tax expense. Q4 FY26 alone showed a loss of ₹315.08 lakhs. Exceptional items of ₹19.51 lakhs (negative) included provisions for labour code changes (₹24.48 lakhs) partially offset by EPCG scheme reversals. Cash flow from operations remained healthy at ₹1,020.48 lakhs. The statutory auditor GSKA & Co. issued an unmodified (clean) opinion.
The company swung to a net loss for FY2026 due to significant deferred tax charges, which is a major concern for shareholders despite positive operating cash flows and marginal revenue growth.